logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2H 2021
Sio Gene Therapies Inc.
Biomarker data from phase I/II study AXO-AAV-GM1
GM1 gangliosidosis
2H 2021
Ayala Pharmaceuticals, Inc.
Interim data from phase II trial of AL101 (TENACITY )
Triple negative breast cancer
2H 2021
Actinium Pharmaceuticals Inc
Proof-of-concept data from Phase I study of Iomab-ACT
CD19 targeted CAR T-cell 19-28z.
Q3 2021
Ocuphire Pharma, Inc.
Top line data from phase III study of Nyxol (LYNX-1)
Night Vision Disturbances
2H 2021
Karyopharm Therapeutics Inc.
Topline data from phase III study evaluating the efficacy and safety for front-line maintenance therapy with XPOVIO (SIENDO)
Advanced or recurrent endometrial cancer
2H 2021
Angion Biomedica Corp.
Topline data from phase II trial examining efficacy of ANG-3777
Reducing acute kidney injury in patients after a cardiac procedure
2H 2021
Decibel Therapeutics, Inc.
Interim results from phase 1b clinical trial of DB-020
Prevention of cisplatin-induced hearing loss
2H 2021
Solid Biosciences Inc.
Clinical outcomes from additional patients of Phase I/II study of SGT-001 microdystrophin gene therapy (IGNITE-DMD)
Duchenne muscular dystrophy
Q3 2021
Travere Therapeutics Inc
36-week interim proteinuria endpoint analysis from phase III study of Sparsentan
Focal Segmental Glomerulosclerosis
2H 2021
EPIX Pharmaceuticals, Inc.
Clinical data from phase I study of EPI-7386
Metastatic castration-resistant prostate cancer
2H 2021
Clene Inc.
Topline data from phase II study of CNM-Au8 (REPAIR-MS)
Multiple Sclerosis
Q3 2021
Graybug Vision, Inc
Topline data from 6-month observational trial extension of ALTISSIMO trial
Patients with anti-VEGF-responsive wet AMD
Q3 2021
Sol-Gel Technologies Ltd.
Top-line data from phase 1 proof-of-concept study of SGT-210
Palmoplantar keratoderma
Q3 2021
Idera Pharmaceuticals, Inc.
Data from phase 2 study of tilsotolimod in combination with ipilimumab and nivolumab (ILLUMINATE-206)
Micro-satellite stable colorectal cancer
Q3 2021
Aerie Pharmaceuticals, Inc.
Topline results from Phase 2b clinical trial of AR-15512
Dry Eye
2H 2021
Aerie Pharmaceuticals, Inc.
Topline data from phase 1 study of AR-13503 Implant
Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)
2H 2021
Amneal Pharmaceuticals, Inc.
Topline data from phase 3 trial of IPX-203
Parkinson's Disease (PD)
2H 2021
Annexon, Inc.
Initial data from Phase 2 trial of ANX005
Huntington Disease (HD)
2H 2021
Annexon, Inc.
Initial data from Phase 2 trial of ANX005
Amyotrophic lateral sclerosis (ALS)
Q3 2021
Apellis Pharmaceuticals, Inc.
Top-line results from Phase 3 study of Intravitreal Pegcetacoplan (DERBY)
Geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Q3 2021
Apellis Pharmaceuticals, Inc.
Top-line results from Phase 3 study of of Intravitreal Pegcetacoplan (OAKS)
Geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
2H 2021
Aligos Therapeutics, Inc
Initial topline results from Phase 1a/1b umbrella trial of ALG-000184-201
Chronic hepatitis B (CHB)
2H 2021
Arena Pharmaceutical Inc.
Topline data from Phase 2 trial of Etrasimod
Alopecia areata (AA)
2H 2021
Actinium Pharmaceuticals Inc
Results from Phase 1/2 proof of concept study of Actimab-A and Venetoclax Combination
Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) age 18 and above
2H 2021
Revance Therapeutics, Inc.
Results from Phase 3, long-term safety study of DaxibotulinumtoxinA (ASPEN-OLS)
Cervical dystonia